Profusa Inc. (PFSA)
Profusa Inc. (PFSA) Stock Price, Analysis & Data
| Cours acheteur | 1.05 |
| Capitalisation boursière | 471.28K |
| Chiffre d’affaires (ttm) | n/a |
| Résultat net (ttm) | -36.56M |
| Bêta | 0.49 |
| EPS (ttm) | -384.07 |
| Ratio P/E (ttm) | n/a |
| P/E prévisionnel | n/a |
| P/B (ttm) | n/a |
| P/S (ttm) | n/a |
| Earnings Date | n/a |
| Cours vendeur | 1.15 |
| Volume | 10,148 |
| Volume moy. (20D) | 348,206 |
| Ouverture | 0.89 |
| Clôture précédente | 0.94 |
| Fourchette du jour | 0.89 - 0.89 |
| Intervalle de 52 semaines | 0.81 - 1297.50 |
| Analyste | n/a |
| Objectif de prix | n/a |
| Dividendes | n/a |
| Date ex-dividende | n/a |
À propos de PFSA
Profusa, Inc., a digital health technology company, develops bioengineered sensors for body to detect and continuously transmit clinical-grade data for personal and medical use in the United States. It offers the Lumee Oxygen Platform to monitor compromised tissue for peripheral artery disease, chronic wounds, and reconstructive surgery. The company researches and develops the Lumee Glucose Platform which is designed to monitor glucose levels in ...
Performance financière
En 2025, le chiffre d’affaires de Profusa s’élevait à 0, soit une hausse de undefined% par rapport aux 0 de l’année précédente. Le bénéfice s’élevait à -35.82M, soit une hausse de 288.11%.
États financiers
2 semaines il y a · InvestorsHub
Profusa Signs Term Sheet for Diagnostics Acquisition and Announces Leadership ChangesProfusa (NASDAQ:PFSA) has signed a non-binding term sheet to acquire a commercial-stage diagnostics company with estimated 2025 net revenue of approximately $111 million, while also reshaping its exec...
